UniQure NV - Company Profile
Powered by 
All the data and insights you need on UniQure NV in one report.
$295
- Save hours of research time and resources with
our up-to-date UniQure NV Strategy Report
- Understand UniQure NV position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
UniQure NV (UniQure) develops and markets gene therapy products. The company develops adeno-associated virus (AAV) based gene therapies using its gene technology platform and offers disease-modifying treatments to patients with severe genetic diseases and other devastating diseases. UniQure’s lead product, AMT-060, is a gene therapy for the treatment of moderately-severe hemophilia B. Its preclinical products include AMT-130, an AAV5 vector for the treatment of Huntington's disease and AMT-150 for Spinocerebellar Ataxia type 3. The company develops a gene platform to bring new disease modifying therapies to patients with genetic diseases. The company conducts drug discovery and preclinical research in collaboration with academic research institutions. UniQure is headquartered in Amsterdam, the Netherlands.
Headquarters
Netherlands
Address
Paasheuvelweg 25a, Amsterdam, Noord-Holland, 1105BP
Website
www.uniqure.com
Telephone
31 20 2406000
No of Employees
480
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
QURE (NASD)
Revenue (2022)
$15.8M
-85.1%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-143.3%
(2022 vs 2021)
Market Cap*
$223.4M
Net Profit Margin (2022)
XYZ
-1,535.3%
(2022 vs 2021)
* As of and is in US$
UniQure NV premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Liver Directed Diseases: |
| Etranacogene dezaparvovec (AMT-060/061) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Regulatory Approval | In November, the company announced the US Food and Drug Administration's clearance of the Investigational New Drug application for AMT-191. |
| 2023 | Contracts/Agreements | In May, the company entered into an agreement to sell a portion of the royalty rights in HEMGENIX to HealthCare Royalty and Sagard Healthcare for US$400 million. |
| 2023 | Contracts/Agreements | In February, the company along with CSL announced the publication in the New England Journal of Medicine of results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX. |
Competitor Comparison
| Key Parameters | UniQure NV | BioMarin Pharmaceutical Inc | Adverum Biotechnologies Inc | bluebird bio Inc | Beacon Therapeutics (USA) Inc |
|---|---|---|---|---|---|
| Headquarters | Netherlands | United States of America | United States of America | United States of America | United States of America |
| City | Amsterdam | Novato | Redwood City | Somerville | Alachua |
| State/Province | Noord-Holland | California | California | Massachusetts | Florida |
| No. of Employees | 480 | 3,401 | 121 | 323 | 102 |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| David Meek | Chairman | Executive Board | 2021 | 59 |
| Matthew Kapusta | Director; Chief Executive Officer | Executive Board | 2016 | 50 |
| Christian Klemt | Chief Financial Officer | Senior Management | 2021 | 50 |
| David Cerveny | Secretary; Chief Legal Officer; General Counsel | Senior Management | 2018 | - |
| Walid Abi-Saab, M.D | Chief Medical Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward